Literature DB >> 15283885

Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy.

Fernando J Bianco1, Daniel Justa, David J Grignon, Wael A Sakr, J Edson Pontes, David P Wood.   

Abstract

High-grade bladder cancer involving the lamina propria is considered superficial disease. This spectrum is generally treated with TUR plus intravesical therapy. However, significant understaging jeopardizes long-term survival and improvements and radical surgery represents a provocative alternative. We evaluated disease-free and cancer-specific survival (CSS) in our cohort of patients with high-grade T1 tumors. A total of 318 patients with bladder cancer underwent radical cystectomy between 1990 and 2000 at our institution. Of these, 66 had cT1 tumors with or without Carcinoma in-situ (CIS). Our multidisciplinary bladder cancer database was queried to perform a multivariate analysis on clinical parameters such as: age, race, sex, cystectomy year, intravesical therapy, angiolymphatic-invasion and tumor upstage in relation to recurrence and survival. The clinical stage was accurate in 44 of the cases (66%). However, 27% were upstaged by cystectomy and 12% of the cT1 + CIS patients had nodal disease. Patients with cT1 tumors plus CIS had a significantly worse CSS. Those with persistent disease after an initial course of BCG therapy appeared to have worse CSS also. At a median follow up of 4 years, overall cancer-specific mortality was 22%, however, pathologic T1 +/- CIS had 92% CSS at 10 years. Our data suggests that some cT1 bladder cancer tumors have assiduous clinical courses evidenced in staging discrepancies. For high-grade tumors, early cystectomy and orthotopic diversion increases life expectancy significantly and should be carry out early rather than late. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15283885     DOI: 10.1016/S1078-1439(03)00144-3

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  15 in total

Review 1.  Management of carcinoma in situ of the bladder: best practice and recent developments.

Authors:  Dominic H Tang; Sam S Chang
Journal:  Ther Adv Urol       Date:  2015-12

2.  Selecting patients for immediate cystectomy.

Authors:  Shahrokh F Shariat
Journal:  Rev Urol       Date:  2007

3.  The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy.

Authors:  John P Stein; David F Penson
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

4.  Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience.

Authors:  Venu Chalasani; Wassim Kassouf; Joseph L Chin; Yves Fradet; Armen G Aprikian; Adrian S Fairey; Eric Estey; Louis Lacombe; Ricardo Rendon; David Bell; Ilias Cagiannos; Darrell Drachenberg; Jean-Baptiste Lattouf; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

Review 5.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

Review 6.  Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited.

Authors:  Matthew J Pagano; Gina Badalato; James M McKiernan
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

7.  Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.

Authors:  Francesco Soria; Francesca Pisano; Paolo Gontero; J Palou; S Joniau; V Serretta; S Larré; S Di Stasi; B van Rhijn; J A Witjes; A Grotenhuis; R Colombo; A Briganti; M Babjuk; V Soukup; P U Malmstrom; J Irani; N Malats; J Baniel; R Mano; T Cai; E Cha; P Ardelt; J Varkarakis; R Bartoletti; G Dalbagni; S F Shariat; E Xylinas; R J Karnes; R Sylvester
Journal:  World J Urol       Date:  2018-08-31       Impact factor: 4.226

Review 8.  Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy.

Authors:  D R Yates; M Rouprêt
Journal:  World J Urol       Date:  2011-05-05       Impact factor: 4.226

Review 9.  Systemic therapy of advanced urothelial cancer.

Authors:  Ulka Vaishampayan
Journal:  Curr Treat Options Oncol       Date:  2009-04-29

10.  Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.

Authors:  Patrick D Evers; Joshua E Logan; Veronica Sills; Arnold I Chin
Journal:  World J Urol       Date:  2013-06-12       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.